Diabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #283).
“Our study shows that treatment regimens incorporating AFREZZA offer glycemic control comparable to conventional regimens, with the added benefits of weight loss and less incidence of hypoglycemia, making AFREZZA a potentially important and useful new treatment option in the diabetes space.”
"Standard mealtime insulin therapies are effective in managing blood sugars in patients with Type 1 diabetes, but are known to cause weight gain and severely low blood sugar levels," said Philip Raskin, M.D., Clifton and Betsy Robinson Chair in Biomedical Research, Southwestern Medical School, University of Texas. "Our study shows that treatment regimens incorporating AFREZZA offer glycemic control comparable to conventional regimens, with the added benefits of weight loss and less incidence of hypoglycemia, making AFREZZA a potentially important and useful new treatment option in the diabetes space."
Diabetes, which affects 26.8 million people in the U.S., is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone produced by the pancreas, normally regulates the body's glucose levels, but in people with diabetes insufficient levels of insulin are produced or the body fails to respond adequately to the insulin it produces. Historically, mealtime insulin therapy regimens have had a number of limitations, including the risk of severe hypoglycemia, the likelihood of weight gain, inadequate post-meal glucose control, the need for complex titration of insulin doses in connection with meals and the need for injections. Additionally, therapies have not mimicked the natural time-action profile of insulin normally seen in healthy individuals and presented challenges in maintaining compliance.
AFREZZA is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with Type 1 and Type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder pre-metered into single use dose cartridges and the light, discreet and easy-to-use AFREZZA Inhaler. Administered at the start of a meal, AFREZZA dissolves immediately upon inhalation and delivers insulin quickly to the blood stream. Peak insulin levels are achieved within 12 to 14 minutes of administration, mimicking the release of meal-time insulin observed in healthy individuals. To date, the AFREZZA clinical program has involved 49 different studies and over 5,000 adult patients.
Global diabetes cases exceed 800 million highlighting urgent need for action